
Drug ‘breakthrough’ gives longest-ever survival in non-resectable liver cancer patients
The IMbrave150 trial found median overall survival was 19.2 months in patients treated with atezo…
The IMbrave150 trial found median overall survival was 19.2 months in patients treated with atezo…